GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gritstone Bio Inc (NAS:GRTS) » Definitions » Beneish M-Score

Gritstone Bio (Gritstone Bio) Beneish M-Score : -4.78 (As of May. 14, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Gritstone Bio Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -4.78 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Gritstone Bio's Beneish M-Score or its related term are showing as below:

GRTS' s Beneish M-Score Range Over the Past 10 Years
Min: -4.78   Med: -2.83   Max: 39.22
Current: -4.78

During the past 8 years, the highest Beneish M-Score of Gritstone Bio was 39.22. The lowest was -4.78. And the median was -2.83.


Gritstone Bio Beneish M-Score Historical Data

The historical data trend for Gritstone Bio's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gritstone Bio Beneish M-Score Chart

Gritstone Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial -1.25 -3.17 9.54 -3.54 -4.00

Gritstone Bio Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.99 -2.66 -3.56 -4.00 -4.78

Competitive Comparison of Gritstone Bio's Beneish M-Score

For the Biotechnology subindustry, Gritstone Bio's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gritstone Bio's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gritstone Bio's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Gritstone Bio's Beneish M-Score falls into.



Gritstone Bio Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Gritstone Bio for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 2.1976+0.528 * 1+0.404 * 0.495+0.892 * 0.1656+0.115 * 1.822
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 6.6428+4.679 * -0.216716-0.327 * 2.72
=-4.78

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Total Receivables was $0.21 Mil.
Revenue was 0.049 + 0.029 + 0.361 + 0.4 = $0.84 Mil.
Gross Profit was 0.049 + 0.029 + 0.361 + 0.4 = $0.84 Mil.
Total Current Assets was $51.85 Mil.
Total Assets was $137.21 Mil.
Property, Plant and Equipment(Net PPE) was $79.15 Mil.
Depreciation, Depletion and Amortization(DDA) was $7.53 Mil.
Selling, General, & Admin. Expense(SGA) was $30.54 Mil.
Total Current Liabilities was $25.87 Mil.
Long-Term Debt & Capital Lease Obligation was $96.47 Mil.
Net Income was -40.385 + -30.818 + -38.434 + -35.256 = $-144.89 Mil.
Non Operating Income was 0 + -0.004 + -0.006 + -0.022 = $-0.03 Mil.
Cash Flow from Operations was -33.567 + -19.508 + -31.087 + -30.963 = $-115.13 Mil.
Total Receivables was $0.57 Mil.
Revenue was 0.542 + 1.327 + 0.436 + 2.761 = $5.07 Mil.
Gross Profit was 0.542 + 1.327 + 0.436 + 2.761 = $5.07 Mil.
Total Current Assets was $154.77 Mil.
Total Assets was $209.95 Mil.
Property, Plant and Equipment(Net PPE) was $35.98 Mil.
Depreciation, Depletion and Amortization(DDA) was $6.77 Mil.
Selling, General, & Admin. Expense(SGA) was $27.76 Mil.
Total Current Liabilities was $24.67 Mil.
Long-Term Debt & Capital Lease Obligation was $44.15 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0.206 / 0.839) / (0.566 / 5.066)
=0.24553 / 0.111725
=2.1976

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(5.066 / 5.066) / (0.839 / 0.839)
=1 / 1
=1

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (51.853 + 79.145) / 137.212) / (1 - (154.765 + 35.98) / 209.952)
=0.045288 / 0.091483
=0.495

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=0.839 / 5.066
=0.1656

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(6.77 / (6.77 + 35.98)) / (7.534 / (7.534 + 79.145))
=0.158363 / 0.086918
=1.822

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(30.54 / 0.839) / (27.76 / 5.066)
=36.400477 / 5.479668
=6.6428

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((96.471 + 25.87) / 137.212) / ((44.151 + 24.672) / 209.952)
=0.89162 / 0.327803
=2.72

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-144.893 - -0.032 - -115.125) / 137.212
=-0.216716

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Gritstone Bio has a M-score of -4.78 suggests that the company is unlikely to be a manipulator.


Gritstone Bio Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Gritstone Bio's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Gritstone Bio (Gritstone Bio) Business Description

Traded in Other Exchanges
Address
5959 Horton Street, Suite 300, Emeryville, CA, USA, 94608
Gritstone Bio Inc is a biotechnology company. The company is engaged in developing personalized cancer immunotherapies to fight multiple cancer types and infectious diseases. It is building a pipeline of Immunotherapies product candidates for patients with solid tumors, which includes GRANITE, SLATE, BiSAb, among others.
Executives
Lawrence Corey director C/O GRITSTONE BIO, INC., 5959 HORTON STREET, SUITE 300, EMERYVILLE CA 94608
Naiyer Rizvi director C/O ARMO BIOSCIENCES, INC., 575 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Elaine V Jones director C/O TARGACEPT, INC., 200 EAST FIRST STREET, SUITE 300, WINSTON-SALEM NC 27101
Clare Fisher director C/O GRITSTONE ONCOLOGY, INC., 5959 HORTON STREET, SUITE 300, EMERYVILLE CA 94608
Steve E. Krognes director 863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010
Shefali Agarwal director C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Vassiliki Economides officer: See Remarks C/O KEZAR LIFE SCIENCES, INC., 4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Erin Jones officer: See Remarks C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608
James Cho officer: Chief Accounting Officer C/O GRITSTONE ONCOLOGY, INC., 5959 HORTON STREET, SUITE 300, EMERYVILLE CA 94608
Raphael Rousseau officer: See Remarks C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608
Roman Yelensky officer: See Remarks C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608
Thomas Woiwode director ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Rahsaan Thompson officer: EVP and General Counsel 233 WILSHIRE BOULEVARD, SUITE 280, SANTA MONICA CA 90401
Vijay Yabannavar officer: See Remarks C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608
Nicholas Simon director 101 MAIN STREET SUITE 1210, CAMBRIDGE MA 02142